Systematic Financial Management LP Has $13.40 Million Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Systematic Financial Management LP raised its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 14.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,612,161 shares of the company's stock after acquiring an additional 206,499 shares during the period. Systematic Financial Management LP owned approximately 0.64% of Maravai LifeSciences worth $13,397,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in shares of Maravai LifeSciences by 310.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company's stock valued at $26,000 after purchasing an additional 2,711 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $32,000. Blue Trust Inc. acquired a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $44,000. Venturi Wealth Management LLC acquired a new position in shares of Maravai LifeSciences during the 3rd quarter valued at $47,000. Finally, Custom Index Systems LLC acquired a new position in shares of Maravai LifeSciences during the 3rd quarter valued at $97,000. Institutional investors own 50.25% of the company's stock.

Insider Activity at Maravai LifeSciences

In related news, insider Carl Hull purchased 175,000 shares of Maravai LifeSciences stock in a transaction on Monday, November 11th. The stock was bought at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares of the company's stock, valued at approximately $987,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group cut Maravai LifeSciences from a "neutral" rating to a "sell" rating and decreased their target price for the stock from $7.00 to $4.25 in a report on Thursday. Morgan Stanley downgraded Maravai LifeSciences from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $11.00 to $10.00 in a report on Tuesday, August 13th. Royal Bank of Canada lowered their price target on Maravai LifeSciences from $17.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday, November 8th. Robert W. Baird lowered their price target on Maravai LifeSciences from $10.00 to $9.00 and set an "outperform" rating on the stock in a report on Friday, November 8th. Finally, UBS Group lifted their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the company a "neutral" rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of "Hold" and a consensus target price of $10.03.

Maravai LifeSciences Stock Down 0.8 %

MRVI traded down $0.04 during trading on Friday, reaching $5.05. 1,217,694 shares of the stock traded hands, compared to its average volume of 2,243,117. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -3.10 and a beta of -0.08. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $4.28 and a fifty-two week high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The stock's 50-day simple moving average is $6.81 and its two-hundred day simple moving average is $7.98.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.